<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089826</url>
  </required_header>
  <id_info>
    <org_study_id>Role of LTOT in Pateints e ILD</org_study_id>
    <nct_id>NCT04089826</nct_id>
  </id_info>
  <brief_title>Long Term Oxygen Therapy in Patients With Interstitial Lung Disease</brief_title>
  <official_title>Role of LTOT in Pateints With ILD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the effect of using long term oxygen therapy in patients with interstitial lung disease
      and chronic hypoxia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      long term oxygen can be used in patients with interstitial lung disease with hypoxia and the
      aim of this study is to k ow whether this will improve life style , exercise tolerance in
      those patients
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea score improvement</measure>
    <time_frame>Baseline</time_frame>
    <description>dyspnea by Modified Medical Research Counsel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life improvement</measure>
    <time_frame>Baseline</time_frame>
    <description>Quality of life by st.George questionnaire</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Long Term Oxygen Therapy</condition>
  <condition>Interstitial Lung Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ILDs who are prescribed for LTOT between eighteen and seventy years old
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  patients with ILD and hypoxia with SO2&lt;88 at room air and PO2 &lt; or equal 7.3k.pa or &lt;
             or equal 8 k.pa in presence of lower limb edema , pulmonary hypertension or
             polycythemia

          -  age group 18 : 70

        Exclusion Criteria :

          -  Causes of chronic respiratory failure other than ILD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Asmaa Mahmoud Mohamed Eltayeb</last_name>
    <phone>01114203879</phone>
    <email>asmaaeltayeb34@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Atef Farouk Elqarn</last_name>
    <phone>01006474200</phone>
  </overall_contact_backup>
  <reference>
    <citation>Cobo-Ibáñez T, López-Longo FJ, Joven B, Carreira PE, Muñoz-Fernández S, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, Muriel ET, Mateos CB, de la Peña Lefebvre PG, Gomez-Gomez A, Nogal LB, Pérez A, Almodovar R, Lojo L, Ruiz-Gutiérrez L, López-Robledillo JC, García de Yébenes MJ, Nuño-Nuño L. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol. 2019 Mar;38(3):803-815. doi: 10.1007/s10067-018-4353-2. Epub 2018 Nov 3.</citation>
    <PMID>30392161</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Asmaa Mahmoud Mohammed Eltayeb</investigator_full_name>
    <investigator_title>Resident at chest department Assiut university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

